Checks and balances between human cytomegalovirus replication and indoleamine-2,3-dioxygenase

被引:13
|
作者
Zimmermann, Albert [1 ]
Hauka, Sebastian [1 ]
Maywald, Marco [1 ]
Vu Thuy Khanh Le [3 ]
Schmidt, Silvia K. [2 ]
Daeubener, Walter [2 ]
Hengel, Hartmut [4 ]
机构
[1] Univ Dusseldorf, Inst Virol, D-40225 Dusseldorf, Germany
[2] Univ Dusseldorf, Inst Med Microbiol & Hosp Hyg, D-40225 Dusseldorf, Germany
[3] Univ Duisburg Essen, Univ Hosp Essen, Inst Virol, D-45147 Essen, Germany
[4] Univ Freiburg, Univ Med Ctr, Inst Virol, D-79104 Freiburg, Germany
来源
JOURNAL OF GENERAL VIROLOGY | 2014年 / 95卷
关键词
PIGMENT EPITHELIAL-CELLS; MICROVASCULAR ENDOTHELIAL-CELLS; INDOLEAMINE 2,3-DIOXYGENASE; INTERFERON-GAMMA; TYROSINE PHOSPHORYLATION; TRYPTOPHAN DEGRADATION; TOXOPLASMA-GONDII; SIGNAL-TRANSDUCER; INHIBITION; VIRUS;
D O I
10.1099/vir.0.061994-0
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Despite a rigorous blockade of interferoal (IFN-gamma) signalling in infected fibroblasts as a mechanism of immune evasion by human cytomegalovirus (HCMV), IFN-gamma induced indoleamine-2,3-dioxygenase (IDO) has been proposed to represent the major antiviral restriction factor limiting HCMV replication in epithelial cells. Here we show that HCMV efficiently blocks transcription of IFN-gamma-induced IDO mRNA both in infected fibroblasts and epithelial cells even in the presence of a preexisting IFN-induced antiviral state. This interference results in severe suppression of IDO bioactivity in HCMV-infected cells and restoration of vigorous HCMV replication. Depletion of IDO expression nonetheless substantially alleviated the antiviral impact of IFN-gamma treatment in both cell types. These findings highlight the effectiveness of this IFN-gamma induced effector gene in restricting HCMV productivity, but also the impact of viral counter-measures.
引用
收藏
页码:659 / 670
页数:12
相关论文
共 50 条
  • [1] Indoleamine-2,3-Dioxygenase activity in experimental human Endotoxemia
    Padberg, J. -S.
    van Meurs, M.
    Kielstein, J. T.
    Martens-Lobenhoffer, J.
    Bode-Boeger, S. M.
    Zijlstra, J. G.
    Kovesdy, C. P.
    Kuempers, P.
    MEDIZINISCHE KLINIK-INTENSIVMEDIZIN UND NOTFALLMEDIZIN, 2012, 107 (04) : 325 - 325
  • [2] Indoleamine-2,3-Dioxygenase in Murine and Human Systemic Lupus Erythematosus
    Sthoeger, Zev
    Sharabi, Amir
    Zinger, Heid
    Asher, Ilan
    Mozes, Edna
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [3] Indoleamine-2,3-dioxygenase in an Immunotherapy Model for Ewing Sarcoma
    Max, Daniela
    Kuehnoel, Caspar D.
    Burdach, Stefan
    Niu, Liguo
    Staege, Martin S.
    Foell, Juergen L.
    ANTICANCER RESEARCH, 2014, 34 (11) : 6431 - 6441
  • [4] RELATIONSHIP BETWEEN INTERFERON-GAMMA, INDOLEAMINE-2,3-DIOXYGENASE AND TRYPTOPHAN
    HEYES, MP
    FASEB JOURNAL, 1991, 5 (14): : 3003 - 3004
  • [5] Importance of Indoleamine-2,3-Dioxygenase in the pathogenesis of pulmonary hypertension
    Cai, Z.
    Van Duin, R. W. B.
    Duncker, Dirk J.
    Merkus, D.
    CARDIOVASCULAR RESEARCH, 2018, 114 : S49 - S49
  • [6] Indoleamine-2,3-dioxygenase modulation of allergic immune responses
    Le, Annie V.
    Broide, David H.
    CURRENT ALLERGY AND ASTHMA REPORTS, 2006, 6 (01) : 27 - 31
  • [7] Indoleamine-2,3-Dioxygenase as a Perioperative Marker of the Immune System
    Bello, Corina
    Heinisch, Paul Philipp
    Mihalj, Maks
    Carrel, Thierry
    Luedi, Markus M.
    FRONTIERS IN PHYSIOLOGY, 2021, 12
  • [8] Immunotolerant indoleamine-2,3-dioxygenase is increased in condyloma acuminata
    Xie, Z.
    Zhang, M.
    Xiong, W.
    Wan, H. Y.
    Zhao, X. C.
    Xie, T.
    Lei, H.
    Lin, Z. C.
    Luo, D. S.
    Liang, X. L.
    Chen, Y. H.
    BRITISH JOURNAL OF DERMATOLOGY, 2017, 177 (03) : 809 - 817
  • [9] The role of indoleamine-2,3-dioxygenase in normal and pathological pregnancies
    Chang, Rui-Qi
    Li, Da-Jin
    Li, Ming-Qing
    AMERICAN JOURNAL OF REPRODUCTIVE IMMUNOLOGY, 2018, 79 (04)
  • [10] Indoleamine-2,3-dioxygenase activity induces neutrophil apoptosis
    K Van der Sluijs
    R Singh
    A Dijkhuis
    M Snoek
    R Lutter
    Critical Care, 15 (Suppl 1):